tradmap

FATE FATE THERAPEUTICS INC

$2.07 +6.15%

Healthcare · Biological Products, (No Diagnostic Substances)

FATE THERAPEUTICS INC (FATE) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $241 million. Shares last traded at $2.07, 28.1% below their 52-week high. Over the past year the stock is up 73.9%. Net profit margin is -2051.1%, below the peer median of 6.3%. Revenue declined 51.2% year over year.

Market Cap
$241M
Shares Out
116.6M
EPS (TTM)
$-2.07
P/E Ratio
P/S Ratio
36.30
P/B Ratio
1.34
Dividend / Share
Dividend Yield
52-Week High
$2.88
52-Week Low
$0.91
Volume
158,759
Avg Vol (3m)
137,821.492

Performance

1W
+5.08%
1M
+9.52%
3M
+91.67%
6M
+90.78%
YTD
+109.85%
1Y
+73.95%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
51.41
SMA (50)
$1.86
SMA (200)
$1.35
Price vs SMA50
+11.14%
Price vs SMA200
+53.18%
ATR (14)
$0.21

Financials

Revenue
$7M
Net Income
$-136M
Gross Margin
Operating Margin
-2222.4%
Net Margin
-2051.1%
Return on Equity
-75.9%
Return on Assets
-47.8%
Current Ratio
5.85
Debt / Equity
0.05
Revenue Growth (YoY)
-51.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.26 2026-05-13
FY 2025 $-1.15 2026-02-26
Q3 2025 $-0.88 2025-11-13
Q2 2025 $-0.61 2025-08-12
Q1 2026 $-0.32 2026-05-13
FY 2025 $-1.64 2026-02-26

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

FATE vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
36.30 / 5.21 med
+596% premium
Net margin vs peers
-2051.1% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.